Mahoney Michael F

BSX CEO Mahoney sells 160,901 shares for $15.0M at blended $93.49; stock down 15.3% from 52-week high; prior BSX sells poorly-timed.

Mahoney Michael F, Chairman, President & CEO of Boston Scientific Corp, executed 2 separate sales totaling 160,901 shares for $15,043,394.38 on 2026-02-02 at a blended average price of $93.49. This reduces his holdings from 1,572,636 shares to 1,411,735 shares, a -10.2% reduction in his stake. His prior 5 trades at BSX have all been sells, and all 5 were poorly timed: none resulted in negative 90-day returns (the benchmark for well-timed insider selling). His cross-ticker record on sells shows 0.00% well-timed rate over 13 prior sales. The current stock price of $91.62 sits -15.3% from the 52-week high of $108.14 and -3.3% down over the prior 30 days, while fundamentals remain solid with revenue of $5,065,000,000.00, net income of $755,000,000.00, and annual revenue growth of +17.6%.

BSX CEO Mahoney sold 164,443 shares for $17,051,135.67 on 2025-06-02 near 52-week highs; prior BSX sales show mixed timing.

Mahoney Michael F, Chairman, President & CEO of Boston Scientific, executed 2 separate sales totaling 164,443 shares for $17,051,135.67 on June 2, 2025, at a blended average price of $103.69, reducing his holdings from 1,641,325 to 1,476,882 shares (a -10.0% reduction). The sales occurred near the stock's 52-week high of $106.66 (current price $103.10 is -3.3% from that peak). His prior 5 trades at BSX show a pattern of repeated selling: 4 sales since November 2024 generated positive 30-day returns (+2.3% to +6.8%) but mixed 90-day outcomes (+21.6%, +21.0%, and two outcomes not yet measurable), with a 0% well-timed rate at the 90-day mark across measurable prior BSX sales. The stock's fundamentals appear robust (revenue $4,663,000,000.00, net income $672,000,000.00, +17.6% annual revenue growth), though the elevated P/E of 75.26 reflects current market pricing; the sale timing proximate to 52-week highs and the CEO's sustained selling pattern warrant investor attention to his conviction regarding forward valuation.

BSX CEO Mahoney sells 164,443 shares for $16.9M on May 1, 2025; retains 1.54M shares post-sale

Michael F Mahoney (Chairman, President & CEO) executed 2 separate open-market sales on 2025-05-01, selling 164,443 shares for $16,851,973.70 at a blended average price of $102.48. His remaining holdings of 1,535,706 shares represent a 9.7% reduction from pre-transaction levels. Across his prior 9 open-market sales (cross-ticker track record), the 90-day well-timed rate is 0.00%, indicating the stock has consistently risen after his sales; at Boston Scientific specifically, 0 of 4 prior measurable sales were well-timed at the 90-day mark, with an average 90-day return of +12.9%. The transaction occurs when BSX trades at $104.24, only 1.8% below its 52-week high of $106.18 and up 16.2% over the trailing 30 days, contrasting with the company's elevated P/E of 76.09 and sustained strong fundamentals (revenue growth +17.6% year-over-year, latest quarterly revenue $4.7B).

CEO Michael Mahoney sells 164,442 shares of BSX at $100.01; holds 1,594,530 shares post-trade.

Michael Mahoney, Chairman, President & CEO of Boston Scientific, sold 164,442 shares at $100.01 on 2025-04-01 for a total value of $16,445,071.54, reducing his holdings by 9.3% to 1,594,530 shares. His prior five sales at BSX (September through November 2024) were all followed by stock appreciation at the 90-day mark, averaging 90d returns of +21.6% and +6.8%, with none qualifying as well-timed; the current sale occurs as the stock is trading at $100.05 compared to its 52-week high of $106.18 and down 4.6% over the past 30 days. The company's fundamentals show strong recent performance with revenue of $4,209,000,000.00, net income of $468,000,000.00, and annual revenue growth of +17.6%, though the stock carries a high valuation at a P/E of 72.50. The transaction reflects a material reduction in the CEO's equity stake but lacks context to determine whether this represents scheduled portfolio management or discretionary timing relative to company trajectory.

Director Mahoney buys 30,000 CVS shares at $66.70; holdings increase 320.6% to 39,356 shares

Michael F. Mahoney, a CVS director, purchased 30,000 shares at $66.70 on 2025-02-18 for a total value of $2,001,000.00, expanding his stake from 9,356 to 39,356 shares—a 320.6% increase in holdings. This represents a meaningful accumulation at a price 16.8% below the 52-week high of $79.76 and follows a 26.2% rise in the stock over the prior 30 days. His prior buy at CVS on 2024-05-02 delivered a 90-day return of +10.7%, and across his full cross-ticker history, his prior buys averaged +10.7% over 90 days with a 100% win rate, suggesting a selective buying discipline. The stock is trading at a P/E of 65.10 against modest annual revenue growth of +4.2% and a narrow net income of $87,000,000.00 on $95.4B in quarterly revenue, warranting scrutiny of whether the accumulated position reflects a conviction call in the current valuation environment or merely captures recent momentum.

CEO Mahoney sells 162,778 shares for $13.8M at $84.75; retains 1.52M shares post-sale

Michael F Mahoney, Chairman, President & CEO of Boston Scientific, executed 2 separate sales totaling 162,778 shares on 2024-11-05 for $13,794,850.92, with a blended average price of $84.75. This represents a -9.7% reduction from his pre-transaction holdings of 1,683,983 shares, bringing post-sale holdings to 1,521,205 shares. His prior 6 open-market sell transactions across all tickers show an average 90-day return of +12.2% after the sales, meaning the stock subsequently rose, indicating these sells were not well-timed (0.00% well-timed rate). At Boston Scientific specifically, his 5 prior trades show 0 of 2 measurable 90-day sells were well-timed; both prior completed 90-day periods after his sells showed positive stock returns. The company reports strong fundamentals with annual revenue growth of +12.3%, though it trades at a P/E of 71.80, which is elevated.

Boston Scientific CEO Michael Mahoney sold 162,777 shares for $13.8M at $84.63 avg, holding 1.57M post-sale.

Michael Mahoney, Chairman, President & CEO of Boston Scientific, executed 2 separate sales totaling 162,777 shares (162.8K shares) for $13,775,791.63 ($13.8M) on 2024-10-07, at a blended average price of $84.63. His holdings declined 9.4% versus pre-transaction levels to 1,572,096 shares (1.57M shares). The stock is currently at $85.84, near its 52-week high of $85.84, and has appreciated 5.2% over the past 30 days and 11.3% over 90 days. Across Mahoney's same-ticker history at BSX, his 3 prior measurable sells posted 0% well-timed outcomes at the 90-day mark, and his cross-ticker sell track record shows an average 90-day return of +12.2%, indicating prior sales were poorly timed (stock rose afterward). This sale occurs in a context of strong near-term price appreciation and a CEO with a pattern of sells that have not anticipated subsequent declines.

CEO Mahoney sells 162,777 shares of BSX at $81.17; retains 1,622,987 shares (1.62M)

Michael F Mahoney, Chairman, President & CEO, sold 162,777 shares (162.8K shares) of Boston Scientific on 2024-09-05 at $81.17, reducing his holdings by 9.1% to 1,622,987 shares (1.62M shares). The transaction occurred near the stock's 52-week high of $81.96, with shares up 10.6% over the prior 30 days and 5.8% over 90 days. Mahoney's prior sales at BSX show a 0% well-timed rate across 3 transactions (all three followed by net 90-day gains), suggesting his recent sell decisions have not captured downside moves. The company itself shows strong fundamentals with $4.1B in latest quarterly revenue, 12.3% annual growth, and a $120.2B market cap, though the P/E of 65.81 reflects elevated valuation relative to near-term earnings.